Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma

Authors

Felipe C. Geyer, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Fresia Pareja, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kathleen A. Burke, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anne M. Schultheis, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yaser R. Hussein, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jiqing Ye, Rochester Regional HealthFollow
Maria R. De Filippo, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Caterina Marchio, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gabriel S. Macedo, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Salvatore Piscuoglio, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Raymond S. Lim, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eugene Toy, Rochester Regional HealthFollow
Rajmohan Murali, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Achim A. Jungbluth, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jorge S. Reis-Filho, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert A. Soslow, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Britta Weigelt, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department

Pathology

Document Type

Article

Publication Title

Histopathology

Abstract

AIMS: Low-grade ovarian endometrioid carcinomas may be associated with high-grade components. Whether the latter are clonally related to and originate from the low-grade endometrioid carcinoma remains unclear. The aim of this study was to use massively parallel sequencing to characterize the genomic landscape and clonal relatedness of an ovarian endometrioid carcinoma containing low-grade and high-grade components. METHODS AND RESULTS: DNA samples extracted from each tumour component (low-grade endometrioid, high-grade anaplastic and high-grade squamous) and matched normal tissue were subjected to targeted massively parallel sequencing with the 410-gene Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing assay. Somatic single nucleotide variants, small insertions and deletions, and copy number alterations were detected with state-of-the-art bioinformatics algorithms, and validated with orthogonal methods. The endometrioid carcinoma and the associated high-grade components shared copy number alterations and four clonal mutations, including SMARCA4 mutations, which resulted in loss of BRG1 protein expression. Subclonal mutations and mutations restricted to single components were also identified, such as distinct TP53 mutations restricted to each histological component. CONCLUSIONS: Histologically distinct components of ovarian endometrioid carcinomas may show intratumour genetic heterogeneity but be clonally related, harbouring a complex clonal composition. In the present case, SMARCA4 mutations were probably early events, whereas TP53 somatic mutations were acquired later in evolution.

First Page

480

Last Page

487

DOI

10.1111/his.13240

Volume

71

Issue

3

Publication Date

9-1-2017

Medical Subject Headings

Aged; Carcinoma, Endometrioid (genetics); Carcinoma, Ovarian Epithelial; DNA Mutational Analysis; Female; Humans; Neoplasms, Glandular and Epithelial (genetics); Ovarian Neoplasms (genetics)

PubMed ID

28417598

Share

COinS